Sciclone Pharmaceuticals, Inc.
Records under this name other than patents Sciclone Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Sciclone Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,207,294 | Treatment of Aspergillus infections with alpha thymosin peptides Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,716,012 | Alpha thymosin peptides as vaccine enhancers Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,724,395 | Treatment of cancer with immune stimulators Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,571,465 | Treatment of cancer with alpha thymosin peptide and PD-1 inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,017,129 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma Formerly held Term ended Term ended Jun 15, 2026 · USPTO record | Term ended | Term ended Jun 15, 2026 | USPTO record |
| US 8,389,680 | Treatment of Aspergillus infections with alpha thymosin peptides Formerly held Term ended Ended no later than Mar 29, 2024 · USPTO record | Term ended | Ended no later than Mar 29, 2024 | USPTO record |
| US 7,297,676 | Thymosin alpha 1 peptide/polymer conjugates Formerly held Term ended Term ended Nov 1, 2022 · USPTO record | Term ended | Term ended Nov 1, 2022 | USPTO record |
| US 7,208,167 | Treatment of hepatitis C with thymosin and peptide combination therapy Formerly held Term ended Term ended Nov 7, 2021 · USPTO record | Term ended | Term ended Nov 7, 2021 | USPTO record |
| US 8,193,152 | Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds Formerly held Lapsed on the fee record Ended Jun 5, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 5, 2020 | USPTO record |
| US 6,462,017 | Method of reducing side effects of chemotherapy in cancer patients Formerly held Term ended Term ended May 1, 2020 · USPTO record | Term ended | Term ended May 1, 2020 | USPTO record |